EQT Private Equity to Acquire Qiagen in All-Cash Takeover Deal

EQT Private Equity and Qiagen: A Strategic Acquisition

In a significant move within the biotechnology sector, EQT Private Equity has unveiled a recommended voluntary all-cash public takeover offer for Qiagen, a global leader in molecular diagnostics and sample preparation. This acquisition marks a thrilling chapter for both EQT and Qiagen, cementing their commitment to advancing healthcare solutions across the globe.

As of October 21, 2026, EQT XI, the latest fund that EQT operates, has a target size of EUR 23 billion, with a potential hard cap of EUR 24 billion. This ambitious fund aims to invest 10-15 percent of its total within this transformative deal. The activation of EQT XI has commenced, with management fees being charged as they embark on this investment journey, highlighting the strategic integration of Qiagen's innovative solutions into EQT's burgeoning portfolio.

EQT X, the preceding fund, is currently running at 85-90 percent investment and is still within its commitment period. As EQT XI kicks off, the management fees will adjust accordingly and will be calculated based on net invested capital, which sets a foundation for financially astute growth moving forward.

Qiagen, renowned for its cutting-edge technologies in genomic analysis and diagnostic testing, stands poised to leverage EQT’s financial acumen and extensive network within the healthcare sector. The collaboration is expected to unlock new opportunities for growth and innovation, enhancing Qiagen's capacity to deliver comprehensive solutions tailored to medical research and clinical settings.

The leadership at EQT is enthusiastic about the potential synergies between the two entities. With EQT’s backing, Qiagen can accelerate its research and development initiatives, thereby driving innovation in diagnostics and contributing to the global healthcare landscape. This partnership reflects EQT's visionary approach to investing in companies that are not just financially robust but also contribute positively to society.

In recent years, the demand for advanced diagnostics and health care solutions has surged dramatically. This trend underscores the importance of having leaders in the biotech field who can adapt and expand their offerings to meet the evolving needs of patients and healthcare providers worldwide. The projected collaboration between EQT and Qiagen is likely to set a benchmark in the industry for strategic acquisitions aimed at substantial growth.

For investors and market watchers, this takeover is not merely about capital; it signals a pivotal shift in how private equity firms can significantly impact vital sectors like healthcare. With EQT's robust investment strategy and Qiagen's innovative offerings, stakeholders can expect an exciting trajectory ahead.

As this acquisition unfolds, the implications on Qiagen's operations, product development, and market positioning will be closely monitored. The biotech community is optimistic that this union will lead to breakthroughs that can accelerate the path to precision medicine. Both entities are committed to pushing the envelope of what is feasible in molecular diagnostics and contributing to improved patient outcomes.

For more information on this announcement, you may contact the EQT Press Office or follow the latest updates via their communications platforms. As they continue to explore the synergies this partnership offers, the partnership will unveil more details on how they plan to reshape the industry landscape in the years to come.

This strategic acquisition by EQT is a strong reminder of the potential embedded within innovative healthcare solutions and the ongoing evolution of investment strategies that prioritize both economic returns and social impact. Stakeholders will undoubtedly be keeping a keen eye on how this interplay of resources and vision translates into real-world advancements in biotechnology and healthcare solutions.